Article
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
Neuro-oncology - 1 Dec 2014
Wiestler Benedikt, Capper David, Hovestadt Volker, Sill Martin, Jones David T W, Hartmann Christian, Felsberg Joerg, Platten Michael, Feiden Wolfgang, Keyvani Kathy, Pfister Stefan M, Wiestler Otmar D, Meyermann Richard, Reifenberger Guido, Pietsch Thorsten, von Deimling Andreas, Weller Michael, Wick Wolfgang
Abstract excerpt
BACKGROUND: Molecular biomarkers including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q codeletion, and O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation may improve prognostication and guide treatment decisions for patients with World Health Organization (WHO) anaplastic gliomas. At present, each marker is individually tested by distinct assays. Illumina Infinium...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
